Featured Jobs
|
Internal Channel Sales Team Lead July Business Services
|
|
Stones River Consulting
|
|
Daybright Financial
|
|
EPIC RPS
|
|
Nova 401(k) Associates
|
|
Experienced Employee Benefits Attorney Shipman & Goodwin LLP
|
|
Daybright Financial
|
|
Relationship Manager – Defined Contributions Daybright Financial
|
|
Regional Sales Director-Heartland July Business Services
|
|
Regional Sales Director-Mid Atlantic July Business Services
|
|
Spectrum Pension Consultants (part of Daybright Financial)
|
|
Independent Retirement
|
|
Director of Regulatory Operations and Compliance PCS Retirement
|
|
EPIC RPS
|
|
Director, Strategic Accounts and Channel Development July Business Services
|
Free Newsletters
“BenefitsLink continues to be the most valuable resource we have at the firm.”
-- An attorney subscriber
|
|
Search the News Archive
|
66 Matching News Items |
| 1. |
Brown & Brown, Inc.
Dec. 7, 2025
"Analysis of the results highlights a benefits landscape shaped by rising costs, evolving workforce needs and a growing emphasis on innovation and sustainability. Finding themselves in this landscape, employers re-emphasized controlling costs for both employee and employer by moving it to the top of their strategic priorities. Attracting and retaining a healthy and engaged workforce, the top priority in last year's survey, dropped to number three "
|
| 2. |
Brown & Brown, Inc.
Nov. 4, 2025
"For fertility benefits to be considered an independent, noncoordinated excepted benefit under the regulations, [FAQs Part 72] confirms the benefits must satisfy [three specific] requirements ... The FAQs also describe situations where fertility benefits can qualify as an excepted benefit under the category of limited excepted benefits. "
|
| 3. |
Brown & Brown, Inc.
Oct. 21, 2025
"[1] New drugs influencing benefits ... [2] Federal regulatory activity impacting drug costs ... [3] Vaccine confusion ... [4] State legislation altering pharmacy benefits ... [5] New and expanding use of GLP-1s ... [6] Anti-inflammatory biosimilar use shifting mix of injectable drugs."
|
| 4. |
Brown & Brown, Inc.
Oct. 17, 2025
"Self-funded and fully insured employers are expected to cover the COVID-19 vaccines for eligible members at no cost to members without limitations on coverage based on medical indication or the requirement provider's prescription. This clarification was confirmed ... ahead of the CDC's formal adoption of the ACIP recommendations."
|
| 5. |
Brown & Brown, Inc.
Oct. 16, 2025
"As a reminder, these annual adjustments are permissive, meaning employers/plan sponsors are not required to adopt [the] plan limit adjustments within their plan. If an employer/plan sponsor chooses to adjust their employee contribution/reimbursement amounts, they should reflect such changes within their accompanying document(s) that describe the plan(s)."
|
| 6. |
Brown & Brown, Inc.
Sept. 29, 2025
"[1] Leverage data analytics for early identification ... [2] Implement robust care management programs ... [3] Adopt a Centers of Excellence (COE) strategy ... [4] Optimize pharmacy benefit management ... [5] Incorporate stop-loss insurance with data-driven underwriting ... [6] Promote employee engagement and health literacy ... [7] Review and update plan design regularly ... [8] Coordinate with point solutions -- but avoid fragmentation."
|
| 7. |
Brown & Brown, Inc.
Sept. 17, 2025
"Self-funded employers are expected to retain flexibility to cover the COVID-19 vaccines at no cost to members. Health plans and pharmacy benefit managers are awaiting confirmation. Fully insured employers, on the other hand, may face more limitations. ... [as they] are subject to the carrier's interpretation of federal and state guidance. If the vaccine is not broadly recommended for healthy individuals under 65, carriers may limit coverage to only those with a medical indication or a provider's prescription."
|
| 8. |
Brown & Brown, Inc.
Sept. 3, 2025
"Generic and biosimilar savings help offset growing brand drug expenses, make medications more accessible for patients and support the sustainability of prescription benefits. This Capsule article explores metrics to monitor the use of generics and biosimilars, examines marketplace changes impacting these metrics and reviews benefit options that support the use of these lower-cost options. How close are your generic and biosimilar metrics to optimal performance levels?"
|
| 9. |
Brown & Brown, Inc.
Aug. 19, 2025
19 pages. Covers [1] Eligibility, [2] Contributions, [3] Distributions and [4] Reporting.
|
| 10. |
Brown & Brown, Inc.
Aug. 5, 2025
"[T]he IRS issued Revenue Procedure 2025-25, announcing the 2026 indexed contribution percentage amount for determining the affordability of an Applicable Large Employer's plan under the [ACA]. The IRS also announced the 2026 inflationary adjustment to the employer shared responsibility payment amounts a few days later. Employers should be aware of the significant increase in both the affordability percentage and the employer shared responsibility payment amounts for 2026."
|
| Next » |
|
Syntax Enhancements for Standard Searches
|